Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

GCT3013-03/EPCORE CLL-1

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome (NCT04623541)

Currently recruiting

BGB-A317-LBL-007-201

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (NCT05609370)

Currently recruiting

LONGBOARD-DB

A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies. (NCT05364021)

Currently recruiting

FORTE F8394-201

A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations (NCT05503797)

Currently recruiting

GS-US-546-5920

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies (NCT04778410)

Recently completed/closed

VELOCITY-HNSCC GS-US-699-7184

A Phase 2 Platform Study of Novel Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status (NCT06727565)

Currently recruiting

SELECT

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-Resistant Temporal Lobe Epilepsy (ACTRN12623000446662)

Currently recruiting

SEL003

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Progressive Supranuclear Palsy (ACTRN12620001254987)

Currently recruiting

Pilot WLM

A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)

Currently recruiting

IIHRepurposing1

A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)

Currently recruiting

EVOLVE

A Phase 2 Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The EvolvE Study) (NCT05774184)

Currently recruiting

BMS [IM011-132]

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) (NCT04857034)

Recently completed/closed

INVOKE-2

A phase 2 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AL002 in participants with Early Alzheimer’s disease (NCT04592874)

No longer recruiting

GS-US-536-5939

A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)

Currently recruiting

CPHE885B12201

A Phase 2 Study of PHE885, a BCMA-directed CAR-T Cell Therapy for Patients with Relapsed and Refractory Multiple Myeloma (NCT05172596)

Currently recruiting

Daratumumab@Home

A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (ACTRN12624001468516)

Currently recruiting

CVAY736Q12201

A phase 2 study to evaluate the efficacy and safety of ianalumab in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapy (NCT05885555)

Currently recruiting

MRTLE-DB

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 via an Implantable Pump and a Cranial Port and Double Lumen Catheter (CIC) in Subjects with Focal Seizures, with Temporal Lobe Onset with or without Secondary Generalization (NCT04153175)

Currently recruiting

GARDEN

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, 4-Arm Study to Investigate Symptoms, Function, Health-Related Quality of Life and Safety With Repeated Subcutaneous Administration of Ponsegromab Versus Placebo In Adult Participants With Heart Failure (NCT05492500)

Currently recruiting

SUPERNUS [RENAISSANCE]

A Phase 2, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients with Treatment Resistant Epilepsy (NCT05518578)

Currently recruiting
5 6 7 8 9